Drug General Information
Drug ID
D05VVX
Former ID
DCL000203
Drug Name
PTC299
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 2 [522680]
Therapeutic Class
Anticancer Agents
Company
PTC Therape
Structure
Download
2D MOL

3D MOL

Formula
C16H12FN3S
Canonical SMILES
C1CSC2=NC(=C(N21)C3=CC=NC=C3)C4=CC=C(C=C4)F
InChI
1S/C16H12FN3S/c17-13-3-1-11(2-4-13)14-15(12-5-7-18-8-6-12)20-9-10-21-16(20)19-14/h1-8H,9-10H2
InChIKey
YOELZIQOLWZLQC-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Vascular endothelial growth factor A Target Info Modulator
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
mTOR signaling pathway
PI3K-Akt signaling pathway
VEGF signaling pathway
Focal adhesion
Pathways in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Renal cell carcinoma
Pancreatic cancer
Bladder cancer
Rheumatoid arthritis
NetPath Pathway IL2 Signaling Pathway
EGFR1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
TSH Signaling Pathway
Leptin Signaling Pathway
FSH Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathway
Pathway Interaction Database Glypican 1 network
HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
S1P3 pathway
Signaling events mediated by TCPTP
S1P1 pathway
Alpha9 beta1 integrin signaling events
Integrins in angiogenesis
VEGFR1 specific signals
HIF-1-alpha transcription factor network
Reactome Platelet degranulation
Regulation of gene expression by Hypoxia-inducible Factor
VEGF ligand-receptor interactions
VEGF binds to VEGFR leading to receptor dimerization
WikiPathways SIDS Susceptibility Pathways
Hypertrophy Model
Endochondral Ossification
Focal Adhesion
Differentiation Pathway
Bladder Cancer
Regulation of Hypoxia-inducible Factor (HIF) by Oxygen
Nifedipine Activity
Aryl Hydrocarbon Receptor
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
Integrated Pancreatic Cancer Pathway
Oncostatin M Signaling Pathway
Allograft Rejection
Integrated Breast Cancer Pathway
Signaling by VEGF
Heart Development
Angiogenesis
References
Ref 522680ClinicalTrials.gov (NCT00911248) PTC299 for Treatment of Neurofibromatosis Type 2. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.